Literature DB >> 25861977

The immunobiology of interleukin-27.

Hiroki Yoshida1, Christopher A Hunter.   

Abstract

Interleukin-27 (IL-27) is a cytokine with strikingly diverse influences on the immune response. Although it was initially linked with the development of Th1 responses, it is now recognized as a potent antagonist of different classes of inflammation through its ability to directly modify CD4(+) and CD8(+) T cell effector functions, to induce IL-10, and to promote specialized T regulatory cell responses. Although this aspect of IL-27 biology has provided insights into how the immune system prevents hyperactivity in the setting of infectious and autoimmune inflammation, in vaccination and cancer models the stimulatory effects of IL-27 on CD8(+) T cell function appear prominent. Additionally, associations between IL-27 and antibody-mediated disease have led to an interest in defining the impact of IL-27 on innate immunity and humoral responses in different disease states. The maturation of this literature has been accompanied by attempts to translate these findings from experimental models into human diseases and by efforts to define where IL-27 might represent a viable therapeutic target.

Entities:  

Keywords:  IL-10; IL-17; autoimmunity; infectious disease; inflammation

Mesh:

Substances:

Year:  2015        PMID: 25861977     DOI: 10.1146/annurev-immunol-032414-112134

Source DB:  PubMed          Journal:  Annu Rev Immunol        ISSN: 0732-0582            Impact factor:   28.527


  162 in total

1.  IL-27 signaling deficiency develops Th17-enhanced Th2-dominant inflammation in murine allergic conjunctivitis model.

Authors:  Xin Chen; Ruzhi Deng; Wei Chi; Xia Hua; Fan Lu; Fang Bian; Ning Gao; Zhijie Li; Stephen C Pflugfelder; Cintia S de Paiva; De-Quan Li
Journal:  Allergy       Date:  2019-01-04       Impact factor: 13.146

2.  Loss of IL-27Rα Results in Enhanced Tubulointerstitial Fibrosis Associated with Elevated Th17 Responses.

Authors:  Gaia M Coppock; Lillian R Aronson; Jihwan Park; Chengxiang Qiu; Jeongho Park; Jonathan H DeLong; Enrico Radaelli; Katalin Suszták; Christopher A Hunter
Journal:  J Immunol       Date:  2020-06-10       Impact factor: 5.422

Review 3.  Interleukin (IL)-12 and IL-23 and Their Conflicting Roles in Cancer.

Authors:  Juming Yan; Mark J Smyth; Michele W L Teng
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-07-02       Impact factor: 10.005

4.  Competitive binding of STATs to receptor phospho-Tyr motifs accounts for altered cytokine responses.

Authors:  Stephan Wilmes; Polly-Anne Jeffrey; Jonathan Martinez-Fabregas; Maximillian Hafer; Paul K Fyfe; Elizabeth Pohler; Silvia Gaggero; Martín López-García; Grant Lythe; Charles Taylor; Thomas Guerrier; David Launay; Suman Mitra; Jacob Piehler; Carmen Molina-París; Ignacio Moraga
Journal:  Elife       Date:  2021-04-19       Impact factor: 8.140

5.  IL-27 confers a protumorigenic activity of regulatory T cells via CD39.

Authors:  Young-Jun Park; Heeju Ryu; Garam Choi; Byung-Seok Kim; Eun Sook Hwang; Hun Sik Kim; Yeonseok Chung
Journal:  Proc Natl Acad Sci U S A       Date:  2019-02-04       Impact factor: 11.205

6.  IL-27: a new target for GVHD prevention.

Authors:  Daniel H Fowler; Shoba Amarnath
Journal:  Blood       Date:  2016-10-20       Impact factor: 22.113

Review 7.  Regulation of myelopoiesis by proinflammatory cytokines in infectious diseases.

Authors:  Yukino Chiba; Izuru Mizoguchi; Hideaki Hasegawa; Mio Ohashi; Naoko Orii; Taro Nagai; Miyaka Sugahara; Yasunori Miyamoto; Mingli Xu; Toshiyuki Owaki; Takayuki Yoshimoto
Journal:  Cell Mol Life Sci       Date:  2017-12-07       Impact factor: 9.261

8.  Protective effects against tumors and infection by interleukin-27 through promotion of expansion and differentiation of hematopoietic stem cells into myeloid progenitors.

Authors:  Naoko Orii; Izuru Mizoguchi; Yukino Chiba; Hideaki Hasegawa; Mio Ohashi; Mingli Xu; Taro Nagai; Nakaba Ochiai; Yuki Mochizuki; Toshiyuki Owaki; Takayuki Yoshimoto
Journal:  Oncoimmunology       Date:  2018-01-15       Impact factor: 8.110

9.  Cutting Edge: IL-27 Attenuates Autoimmune Neuroinflammation via Regulatory T Cell/Lag3-Dependent but IL-10-Independent Mechanisms In Vivo.

Authors:  Dongkyun Kim; Hongnga T Le; Quang Tam Nguyen; Sohee Kim; Juyeun Lee; Booki Min
Journal:  J Immunol       Date:  2019-01-30       Impact factor: 5.422

Review 10.  IL-27-induced modulation of autoimmunity and its therapeutic potential.

Authors:  Rakeshchandra R Meka; Shivaprasad H Venkatesha; Steven Dudics; Bodhraj Acharya; Kamal D Moudgil
Journal:  Autoimmun Rev       Date:  2015-08-05       Impact factor: 9.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.